CODX: Co-Diagnostics Projected Price to Earnings

Co-Diagnostics, Inc. (CODX) combines bioethics with environmental safety, although the post-pandemic slump and FDA regulations are forcing a diversification of diagnostics. The company's forward P/E NTM reveals hidden trading dynamics, where the value of 0.00 serves as the baseline indicator for the current valuation. Financial results are based on the licensing of molecular technologies and the sale of PCR systems to medical centers.

Market Cap to Projected Earnings: codiagnostics.com (CODX) for 07/04/2022 - 11/14/2026

Analytical breakdowns and data insights for company CoDx (CODX)

- stock value and consensus price forecast:

Price Chart Co-Diagnostics|CODX - Price Target Chart

- market capitalization information:

Market Valuation Co-Diagnostics Inc|CODX - Total Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Co-Diagnostics|CODX - Book Valuation of Business|Market Capitalization to Book Value Ratio codiagnostics.com|CODX - Company Total Asset Base

- debt level and financial liquidity data:

- company profitability and valuation multiples indicators:

CODX - Company Profit|Projected Future Earnings Co-Diagnostics, Inc.|CODX - Business Payback Period|Forward P/E Multiple Co-Diagnostics Corp|CODX - PEG Multiple|EV/EBITDA Multiple Co-Diagnostics Inc|CODX - Operating profit before depreciation charges|Earnings per share for the last twelve months Co-Diagnostics|CODX - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months codiagnostics.com|CODX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Co-Diagnostics, Inc.

- revenue and sales proceeds data:

CODX - Company Gross Revenue|Company Future Sales Volume Co-Diagnostics|CODX - Market Cap to Sales Volume|Forward P/S Multiple Co-Diagnostics Inc

Fundamental company analysis:CODX Co-Diagnostics

Forward P/E measures the current share price relative to projected net income, allowing investors to assess the market discount or premium for future business growth. By analyzing the expected price-to-earnings ratio of Co-Diagnostics, Inc. (CODX), one can observe how the risk of declining revenue from diagnostic tests impacts the valuation of Co-Diagnostics, Inc. (CODX) stability amidst fierce competition.

Competitors of Co-Diagnostics, Inc. (CODX)